2-cyclohexyl-4-phenyl-piperidine | 1241504-94-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-cyclohexyl-4-phenyl-piperidine
• 英文别名: (2S,4R)-2-cyclohexyl-4-phenylpiperidine；Cis-2-cyclohexyl-4-phenylpiperidine
• CAS: 1241504-94-8
• 化学式: C₁₇H₂₅N
• 分子量: 243.392
• InChiKey: ZZXYRDFIQROERL-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-cyclohexyl-4-phenyl-piperidine 、 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Discovery of pyrrolidine-based β-secretase inhibitors: Lead advancement through conformational design for maintenance of ligand binding efficiency

  摘要：

  We have developed a novel series of pyrrolidine derived BACE-1 inhibitors. The potency of the weak initial lead structure was enhanced using library-based SAR methods. The series was then further advanced by rational design while maintaining a minimal ligand binding efficiency threshold. Ultimately, the co-crystal structure was obtained revealing that these inhibitors interacted with the enzyme in a unique fashion. In all, the potency of the series was enhanced by 4 orders of magnitude from the HTS lead with concomitant increases in physical properties needed for series advancement. The progression of these developments in a systematic fashion is described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.024
• 作为产物：
  描述：

  benzyl 2-cyclohexyl-4-phenylpiperidine-1-carboxylate 在 钯 IPA Hexanes 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 2-cyclohexyl-4-phenyl-piperidine
  参考文献：
  名称：

  Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease

  摘要：

  本发明涉及式(I)的螺环吡咯烷化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶涉及的疾病，例如阿尔茨海默病方面具有用途。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶涉及的这些疾病方面使用这些化合物和组合物。

  公开号：

  US08865701B2

文献信息

• [EN] SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE DE TYPE SPIROPYRROLIDINE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK SHARP & DOHME

  公开号：WO2010094242A1

  公开（公告）日：2010-08-26

  The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的螺环吡咯烷化合物，它们是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease
  申请人：Liu Kun

  公开号：US08865701B2

  公开（公告）日：2014-10-21

  The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的螺环吡咯烷化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶涉及的疾病，例如阿尔茨海默病方面具有用途。本发明还涉及包含这些化合物的制药组合物以及在治疗β-分泌酶酶涉及的这些疾病方面使用这些化合物和组合物。
• US8865701B2
  申请人：——

  公开号：US8865701B2

  公开（公告）日：2014-10-21
• US9505739B2
  申请人：——

  公开号：US9505739B2

  公开（公告）日：2016-11-29
• Discovery of pyrrolidine-based β-secretase inhibitors: Lead advancement through conformational design for maintenance of ligand binding efficiency
  作者：Shawn J. Stachel、Thomas G. Steele、Alessia Petrocchi、Sharie J. Haugabook、Georgia McGaughey、M. Katharine Holloway、Timothy Allison、Sanjeev Munshi、Paul Zuck、Dennis Colussi、Katherine Tugasheva、Abigail Wolfe、Samuel L. Graham、Joseph P. Vacca

  DOI：10.1016/j.bmcl.2011.11.024

  日期：2012.1

  We have developed a novel series of pyrrolidine derived BACE-1 inhibitors. The potency of the weak initial lead structure was enhanced using library-based SAR methods. The series was then further advanced by rational design while maintaining a minimal ligand binding efficiency threshold. Ultimately, the co-crystal structure was obtained revealing that these inhibitors interacted with the enzyme in a unique fashion. In all, the potency of the series was enhanced by 4 orders of magnitude from the HTS lead with concomitant increases in physical properties needed for series advancement. The progression of these developments in a systematic fashion is described. (C) 2011 Elsevier Ltd. All rights reserved.